Megan McNamara

Positions:

Assistant Professor of Medicine

Medicine, Medical Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 2010

University of North Carolina at Chapel Hill School of Medicine

Internal Medicine Residency, Medicine

Duke University School of Medicine

Hematology/Oncology Fellowship, Medicine

Duke University School of Medicine

Grants:

PCF Young Investigator Award

Administered By
Medicine, Medical Oncology
Role
Principal Investigator
Start Date
End Date

A Phase 1b/2 Study of Enzalutamide Plus CC-115 in Men with Castration-Resistant Prostate Cancer (CRPC); Sponsor ¿ Memorial Sloan Kettering Cancer Center

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

Publications:

The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.

BACKGROUND: Until 2015, androgen deprivation therapy (ADT) alone was the standard-of-care for metastatic hormone-sensitive prostate cancer (mHSPC). In 2015, the CHAARTED and STAMPEDE-Docetaxel studies demonstrated marked survival benefit with the addition of docetaxel to ADT in the mHSPC setting, leading to a change in the standard-of-care for mHSPC. The recent LATITUDE and STAMPEDE-Abiraterone trials showed similar substantial improvement in survival with the addition of abiraterone plus prednisone to ADT in this space. METHODS: We conducted a review of the randomized phase III studies that have investigated either the addition of docetaxel or abiraterone to ADT in patients with mHSPC. RESULTS: We describe the study designs, key eligibility criteria, and key results for the CHAARTED, STAMPEDE-Docetaxel, GETUG-AFU 15, LATITUDE, and STAMPEDE-Abiraterone clinical trials. We compare the data for abiraterone/prednisone plus ADT in mHSPC with the evidence for docetaxel plus ADT in these patients. Finally, we discuss several factors that should be considered when choosing between docetaxel/ADT or abiraterone/prednisone/ADT in mHSPC. CONCLUSIONS: The management of mHSPC is evolving. Abiraterone plus prednisone in addition to ADT has emerged as an alternative standard-of-care to docetaxel plus ADT, and ongoing trials should clarify whether combination vs. sequential approaches with AR-targeting agents and taxane chemotherapy are preferred for initial management in the hormone-sensitive setting.
Authors
McNamara, M; Sweeney, C; Antonarakis, ES; Armstrong, AJ
MLA Citation
McNamara, Megan, et al. “The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation..” Prostate Cancer Prostatic Dis, vol. 21, no. 3, Sept. 2018, pp. 306–18. Pubmed, doi:10.1038/s41391-017-0014-9.
URI
https://scholars.duke.edu/individual/pub1293589
PMID
29263421
Source
pubmed
Published In
Prostate Cancer Prostatic Dis
Volume
21
Published Date
Start Page
306
End Page
318
DOI
10.1038/s41391-017-0014-9